Evaluation of donepezil in Alzheimer's disease - Experience from an Australian memory clinic

被引:0
|
作者
Mador, Julie [1 ]
Hecker, Jane [1 ]
Clark, Michael [1 ]
机构
[1] Flinders Univ S Australia, Repatriat Gen Hosp, Dept Rehabil & Aged Care, Daw Pk, Australia
关键词
D O I
10.1111/j.1741-6612.2003.tb00486.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: To describe our experience using cholinesterase inhibitors for mild-moderate Alzheimer's disease in a memory clinic. In particular we reviewed response in cognition, activities of daily living and quality of life for patients. Design: A prospective descriptive study with patients and carers being assessed before and 3-6 months after commencing treatment with a cholinesterase inhibitor. Setting: Memory clinic at Repatriation General Hospital, Adelaide. Subjects: Sixty-four consecutive patients with mild-moderate Alzheimer's disease commencing treatment with a cholinesterase inhibitor and their carers. Outcome Measures: The primary outcome was a change in cognition as measured 6y the Mini-Mental Status Examnination (MMSE). Secondary outcomes were The Alzheimer's Disease Functional Assessment and Change Scale (ADFACS), patient self-assessed measures of quality of life (Dementia Quality of Life Instrument (DQOL) with sub-scales in self-esteem, positive affect, negative affect, belonging and aesthetics, and a five point likert scale of overall quality of life (QOL)) and carer assessed proxy direct scaling of patient quality of life. Results: All patients were commenced on Donepezil. Fifty-four (84%) patients remained on drug treatment and completed the study with follow-up at an average of 13 weeks. Ten patients (16%) stopped treatment due to side-effects or non-compliance. There was a mean change of 1.1 points on the MMSE (p < 0.05) and a small but significant (p < 0.05) improvement in the positive affect sub-scale of the DQOL. There were no improvements in other sub-scales of the DQOL or overall quality of life. A similar number of patients improved 14 (26%) in activities of daily living as those who deteriorated 12 (22%) with the majority 28 (52%) remaining unchanged. Conclusion: Donepezil has a beneficial effect on cognition and affect when used in the setting of a memory clinic. There was little evidence to suggest an improvement in activities of daily living and overall quality of life.
引用
收藏
页码:146 / 150
页数:5
相关论文
共 50 条
  • [41] Effectiveness of donepezil in treating Alzheimer's disease
    Garcia, A
    CANADIAN FAMILY PHYSICIAN, 1999, 45 : 1858 - 1859
  • [42] The effects of donepezil in Alzheimer's disease -: Results from a multinational trial
    Burns, A
    Rossor, M
    Hecker, J
    Gauthier, S
    Petit, H
    Möller, HJ
    Rogers, SL
    Friedhoff, LT
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (03) : 237 - 244
  • [43] Economic evaluation of donepezil in moderate to severe Alzheimer disease
    van Hout, HPJ
    Bosmans, JE
    Stalman, WAB
    NEUROLOGY, 2005, 64 (07) : 1320 - 1320
  • [44] Economic evaluation of donepezil in moderate to severe Alzheimer disease
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Hux, M
    Xu, Y
    Schwam, EM
    Shah, S
    Mastey, V
    NEUROLOGY, 2004, 63 (04) : 644 - 650
  • [45] Alzheimer's Disease Genetics: From the Bench to the Clinic
    Karch, Celeste M.
    Cruchaga, Carlos
    Goate, Alison M.
    NEURON, 2014, 83 (01) : 11 - 26
  • [46] Memory impairment evaluation in incipient Alzheimer's disease
    Ivanoiu, A
    Adam, S
    Van der Linden, M
    Juillerat, AC
    Jacquemin, A
    Godfrind, G
    Prairial, C
    Mulligan, R
    George, M
    Bechet, S
    Salmon, E
    Seron, X
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 71 (01): : 141 - 141
  • [47] Alzheimer's Disease Donepezil also advanced disease effectively
    Krome, Susanne
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2012, 80 (08) : 423 - 423
  • [48] Costs of diagnosing early Alzheimer's disease in three European memory clinic settings: Results from the precision medicine in Alzheimer's disease project
    Wimo, Anders
    Kirsebom, Bjorn-Eivind
    Timon-Reina, Santiago
    Vromen, Ellen
    Selnes, Per
    Bon, Jaka
    Emersic, Andreja
    Kramberger, Milica Gregoric
    Speh, Andreja
    Visser, Pieter Jelle
    Winblad, Bengt
    Fladby, Tormod
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2024, 39 (07)
  • [49] The safety and tolerability of donepezil in patients with Alzheimer's disease
    Jackson, S
    Ham, RJ
    Wilkinson, D
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 : 1 - 8
  • [50] Donepezil for dementia due to Alzheimer's disease (Review)
    Birks, J
    Harvey, RJ
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01):